The arsenal of pathogens and antivirulence therapeutic strategies for disarming them

被引:46
作者
Brannon, John R. [1 ]
Hadjifrangiskou, Maria [1 ,2 ]
机构
[1] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Div Mol Pathogenesis, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Dept Urol Surg, Nashville, TN 37232 USA
关键词
virulence factors; antivirulence therapeutics; biofilms; regulation; Escherichia coli; quorum sensing; persister cells; UROPATHOGENIC ESCHERICHIA-COLI; URINARY-TRACT-INFECTION; CLOSTRIDIUM-DIFFICILE INFECTION; III SECRETION SYSTEM; BUNDLE-FORMING PILUS; INTRACELLULAR BACTERIAL COMMUNITIES; SALMONELLA-TYPHIMURIUM VIRULENCE; INFANT INTESTINAL MICROBIOTA; ENTERICA SEROVAR TYPHIMURIUM; SMALL-MOLECULE INHIBITORS;
D O I
10.2147/DDDT.S98939
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Pathogens deploy an arsenal of virulence factors (VFs) to establish themselves within their infectious niche. The discovery of antimicrobial compounds and their development into therapeutics has made a monumental impact on human and microbial populations. Although humans have used antimicrobials for medicinal and agricultural purposes, microorganism populations have developed and shared resistance mechanisms to persevere in the face of classical antimicrobials. However, a positive substitute is antivirulence therapy; antivirulence therapeutics prevent or interrupt an infection by counteracting a pathogen's VFs. Their application can reduce the use of broad-spectrum antimicrobials and dampen the frequency with which resistant strains emerge. Here, we summarize the contribution of VFs to various acute and chronic infections. In correspondence with this, we provide an overview of the research and development of antivirulence strategies.
引用
收藏
页码:1795 / 1806
页数:12
相关论文
共 185 条
[1]   The broadly conserved regulator PhoP links pathogen virulence and membrane potential in Escherichia coli [J].
Alteri, Christopher J. ;
Lindner, Jonathon R. ;
Reiss, Daniel J. ;
Smith, Sara N. ;
Mobley, Harry L. T. .
MOLECULAR MICROBIOLOGY, 2011, 82 (01) :145-163
[2]   Mucosal Immunization with Iron Receptor Antigens Protects against Urinary Tract Infection [J].
Alteri, Christopher J. ;
Hagan, Erin C. ;
Sivick, Kelsey E. ;
Smith, Sara N. ;
Mobley, Harry L. T. .
PLOS PATHOGENS, 2009, 5 (09)
[3]   Intracellular bacterial biofilm-like pods in urinary tract infections [J].
Anderson, GG ;
Palermo, JJ ;
Schilling, JD ;
Roth, R ;
Heuser, J ;
Hultgren, SJ .
SCIENCE, 2003, 301 (5629) :105-107
[4]   The promise and peril of chemical probes [J].
Arrowsmith, Cheryl H. ;
Audia, James E. ;
Austin, Christopher ;
Baell, Jonathan ;
Bennett, Jonathan ;
Blagg, Julian ;
Bountra, Chas ;
Brennan, Paul E. ;
Brown, Peter J. ;
Bunnage, Mark E. ;
Buser-Doepner, Carolyn ;
Campbell, Robert M. ;
Carter, Adrian J. ;
Cohen, Philip ;
Copeland, Robert A. ;
Cravatt, Ben ;
Dahlin, Jayme L. ;
Dhanak, Dashyant ;
Edwards, Aled M. ;
Frye, Stephen V. ;
Gray, Nathanael ;
Grimshaw, Charles E. ;
Hepworth, David ;
Howe, Trevor ;
Huber, Kilian V. M. ;
Jin, Jian ;
Knapp, Stefan ;
Kotz, Joanne D. ;
Kruger, Ryan G. ;
Lowe, Derek ;
Mader, Mary M. ;
Marsden, Brian ;
Mueller-Fahrnow, Anke ;
Mueller, Susanne ;
O'Hagan, Ronan C. ;
Overington, John P. ;
Owen, Dafydd R. ;
Rosenberg, Saul H. ;
Roth, Brian ;
Ross, Ruth ;
Schapira, Matthieu ;
Schreiber, Stuart L. ;
Shoichet, Brian ;
Sundstrom, Michael ;
Superti-Furga, Giulio ;
Taunton, Jack ;
Toledo-Sherman, Leticia ;
Walpole, Chris ;
Walters, Michael A. ;
Willson, Timothy M. .
NATURE CHEMICAL BIOLOGY, 2015, 11 (08) :536-541
[5]  
ASHFORD WA, 1976, LANCET, V2, P657
[6]   Type IV pili, transient bacterial aggregates, and virulence of enteropathogenic Escherichia coli [J].
Bieber, D ;
Ramer, SW ;
Wu, CY ;
Murray, WJ ;
Tobe, T ;
Fernandez, R ;
Schoolnik, GK .
SCIENCE, 1998, 280 (5372) :2114-2118
[7]  
Bigger JW, 1944, LANCET, V2, P497
[8]   Forced Resurgence and Targeting of Intracellular Uropathogenic Escherichia coli Reservoirs [J].
Blango, Matthew G. ;
Ott, Elizabeth M. ;
Erman, Andreja ;
Veranic, Peter ;
Mulvey, Matthew A. .
PLOS ONE, 2014, 9 (03)
[9]   Persistence of Uropathogenic Escherichia coli in the Face of Multiple Antibiotics [J].
Blango, Matthew G. ;
Mulvey, Matthew A. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (05) :1855-1863
[10]   Molecular variation among type IV pilin (bfpA) genes from diverse enteropathogenic Escherichia coli strains [J].
Blank, TE ;
Zhong, HL ;
Bell, AL ;
Whittam, TS ;
Donnenberg, MS .
INFECTION AND IMMUNITY, 2000, 68 (12) :7028-7038